Generic placeholder image

Current Indian Science

Editor-in-Chief

ISSN (Print): 2210-299X
ISSN (Online): 2210-3007

Research Article

Chronic Inflammatory Pain Modulating Potential of Rubiadin: In-vivo, In-vitro and In-silico Investigations

Author(s): Atul R. Chopade, Suraj N. Mali*, Vijay R. Salunkhe, Madhav R. Burade and Prakash M. Somade

Volume 1, 2023

Published on: 25 January, 2023

Page: [1 - 10] Pages: 10

DOI: 10.2174/2210299X01666220914113809

open access plus

Abstract

Background: The study model of chronic musculoskeletal inflammatory pain, Rubiadin [1,3-dihydroxy-2-methylanthracene-9,10-dione] choice of a drug, aimed to evaluate the anti-hyperalgesic effects.

Objective: To induce gastrocnemius muscle-stimulated hyperalgesia, 3% carrageenan was injected intraperitoneally.

Methods: The response to heat and mechanical stimuli was monitored for 9 days. The effect of 1st dose of rubiadin started monitoring after the 14th day of carrageenan injection and continued monitoring until the 22nd day. After the administration of rubiadin intraperitoneally, antihyperanalgesic activity was observed.

Results: Furthermore, increasing the temperature and mechanical threshold supports histopathological observations with extreme reduction in prostaglandin E2 (PGE2) level.

Conclusion: The objective is to observe anti-inflammatory and anti-hyperalgesic activity of rubiadin in a pain model that is initiated via supraspinal or spinal neuronal mechanisms, predominantly by inhibition of PEG2. Rubiadin provides a wide range of activities in the treatment of chronic muscle pain and chronic muscular inflammation.

Keywords: Rubiadin, Anti-hyperalgesic activity, Chronic muscle pain, Anti-inflammatroy, In-silico, Docking, Cronic musculoskeletal inflammatory pain.

Next »

© 2023 Bentham Science Publishers | Privacy Policy